切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2025, Vol. 14 ›› Issue (04) : 364 -369. doi: 10.3877/cma.j.issn.2095-3224.2025.04.009

综述

中药调控肠癌干细胞抑制结直肠恶性肿瘤进展的研究现状
柯若影1, 王培1,2, 周炳文1,2, 樊志敏1,2,()   
  1. 1210022 南京中医药大学附属南京中医院肛肠科
    2210022 南京,江苏省中医肛肠疾病临床医学创新中心
  • 收稿日期:2025-02-18 出版日期:2025-08-25
  • 通信作者: 樊志敏
  • 基金资助:
    国家自然科学基金项目(No. 82305156); 江苏省自然科学基金项目(No. BK20230162); 江苏省省级重点研发计划(社会发展)(No. BE2021611)

Current research on the role of traditional Chinese medicine in modulating colorectal cancer stem cells to impede the progression of colorectal cancer

Ruoying Ke1, Pei Wang1,2, Bingwen Zhou1,2, Zhimin Fan1,2,()   

  1. 1Department of Anorectal, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, China
    2Jiangsu Clinical Innovation Center for Anorectal Diseases of Traditional Chinese Medicine, Nanjing 210022, China
  • Received:2025-02-18 Published:2025-08-25
  • Corresponding author: Zhimin Fan
引用本文:

柯若影, 王培, 周炳文, 樊志敏. 中药调控肠癌干细胞抑制结直肠恶性肿瘤进展的研究现状[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(04): 364-369.

Ruoying Ke, Pei Wang, Bingwen Zhou, Zhimin Fan. Current research on the role of traditional Chinese medicine in modulating colorectal cancer stem cells to impede the progression of colorectal cancer[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(04): 364-369.

肠癌干细胞(CCSCs)作为结直肠癌中具有自我更新和多向分化能力的致瘤细胞亚群,是导致肿瘤复发、转移和耐药的关键因素。近年研究表明,中药可通过调控CCSCs相关信号通路、影响干性标志物表达及抑制增殖等机制发挥抗结直肠癌作用。本文系统综述中药调控CCSCs的研究进展,为结直肠癌治疗提供新的策略和理论依据。

Colorectal cancer stem cells (CCSCs), as a subpopulation of tumorigenic cells with self-renewal and multi-directional differentiation capabilities in colorectal cancer, are the key factors leading to tumor recurrence, metastasis and drug resistance. Recent studies have shown that traditional Chinese medicine can exert anti-colorectal cancer effects through mechanisms such as regulating CCSCs-related signaling pathways, influencing the expression of stemness markers and inhibiting proliferation. This article systematically reviews the research progress of traditional Chinese medicine in regulating CCSCs, providing new strategies and theoretical basis for the treatment of colorectal cancer.

[1]
姚宏伟,孙应实,张晓燕, 等. 结直肠癌多学科综合治疗协作组诊疗模式中国专家共识(2023版)[J]. 中国实用外科杂志, 2024, 44(1): 1-16.
[2]
Baidoun F, Elshiwy K, Elkeraie Y, et al. Colorectal cancer epidemiology: recent trends and impact on outcomes[J]. Curr Drug Targets, 2021, 22(9): 998-1009.
[3]
Abedizadeh R, Majidi F, Khorasani HR, et al. Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments[J]. Cancer Metastasis Rev, 2024, 43(2): 729-753.
[4]
Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics[J]. Trends Pharmacol Sci, 2023, 44(4): 222-236.
[5]
Zeuner A, Todaro M, Stassi G, et al. Colorectal cancer stem cells: from the crypt to the clinic[J]. Cell Stem Cell, 2014, 15(6): 692-705.
[6]
Radu P, Zurzu M, Tigora A, et al. The impact of cancer stem cells in colorectal cancer[J]. Int J Mol Sci, 2024, 25(8): 4140.
[7]
Yang L, Shi P, Zhao G, et al. Targeting cancer stem cell pathways for cancer therapy[J]. Signal Transduct Target Ther, 2020, 5(1): 8.
[8]
Li S, Chen X, Shi H, et al. Tailoring traditional Chinese medicine in cancer therapy[J]. Mol Cancer, 2025, 24(1): 27.
[9]
郭敏,余文燕,朱柰澄, 等. 中医药基于信号通路调控结直肠癌侵袭转移研究进展[J]. 中国实验方剂学杂志, 2025, 31(4): 323-330.
[10]
Jahanafrooz Z, Mosafer J, Akbari M, et al. Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment[J]. J Cell Physiol, 2020, 235(5): 4153-4166.
[11]
Ricci-Vitiani L, Pagliuca A, Palio E, et al. Colon cancer stem cells[J]. Gut, 2008, 57(4): 538-548.
[12]
谢丽琼,王培术,何正秋, 等. "肿瘤干细胞"视角下论伏邪与肿瘤发生学[J]. 四川中医, 2020, 38(5): 44-47.
[13]
陈玉,肖海娟,王惠玲, 等. 基于伏邪理论探讨恶性肿瘤发病机制[J]. 陕西中医, 2022, 43(12): 1760-1762.
[14]
程海波,吴勉华. 周仲瑛教授"癌毒"学术思想探析[J]. 中华中医药杂志, 2010, 25(6): 866-869.
[15]
廖勉勉,王志宇,张奉学, 等. 基于肿瘤干细胞探讨中医癌毒病机学说[J]. 世界中医药, 2021, 16(20): 3058-3062.
[16]
徐聂,曾永军. 结直肠癌干细胞和肿瘤微环境的相互影响及靶向策略[J]. 肿瘤防治研究, 2022, 49(10): 1077-1081.
[17]
罗安明,戎志斌. 论癌症归属中医"痹痰"的范畴[J]. 中国中医基础医学杂志, 2015, 21(1): 14-15.
[18]
叶敏,施俊. 从古典文献看中医痰与肿瘤干细胞"干性"的关系[J]. 中国医药导报, 2016, 13(28): 80-82.
[19]
Du L, Cheng Q, Zheng H, et al. Targeting stemness of cancer stem cells to fight colorectal cancers[J]. Semin Cancer Biol, 2022, 82: 150-161.
[20]
Pan T, Xu J, Zhu Y. Self-renewal molecular mechanisms of colorectal cancer stem cells[J]. Int J Mol Med, 2017, 39(1): 9-20.
[21]
毛肖瑜,阮小娇. 连翘苷通过Wnt/β-catenin通路抑制体内外结肠癌增殖和干细胞特性[J]. 浙江中医药大学学报, 2023, 47(8): 843-851.
[22]
魏丽慧,方翌,沈阿灵, 等. 片仔癀对大肠癌干细胞自我更新及致瘤能力的抑制作用[J]. 中华中医药杂志, 2022, 37(1): 465-468.
[23]
Song L, Li Z, Liu W, et al. Crosstalk between Wnt/β-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy[J]. Cancer Biol Ther, 2015, 16(1): 1-7.
[24]
雷楠,熊思会,谭溧, 等. 野黄芩苷通过hedgehog信号通路抑制结肠肿瘤干细胞分化的研究[J]. 中国中药杂志, 2020, 45(7): 1676-1683.
[25]
Agarwal E, Brattain MG, Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer[J]. Cell Signal, 2013, 25(8): 1711-1719.
[26]
张晶晶,方翌,刘丽雅, 等. 半枝莲抑制大肠癌干细胞自我更新及成瘤能力[J]. 福建中医药, 2021, 52(1): 41-45.
[27]
Mokhtari RB, Ashayeri N, Baghaie L, et al. The hippo pathway effectors YAP/TAZ-TEAD oncoproteins as emerging therapeutic targets in the tumor microenvironment[J]. Cancers (Basel), 2023, 15(13): 3468.
[28]
韩甜甜,李丹华,林丽珠, 等. 祛瘀解毒汤对结肠癌hct116干细胞的抑制作用研究[J]. 中药材, 2020, 43(3): 694-698.
[29]
Orlandi G, Roncucci L, Carnevale G, et al. Different roles of apoptosis and autophagy in the development of human colorectal cancer[J]. Int J Mol Sci, 2023, 24(12): 10201.
[30]
Sipos F, Műzes G. Interconnection of CD133 stem cell marker with autophagy and apoptosis in colorectal cancer[J]. Int J Mol Sci, 2024, 25(20): 11201.
[31]
李成军,沈光辉. 黄芪多糖通过诱导自噬作用促进结肠癌干细胞凋亡的机制[J]. 中华中医药杂志, 2022, 37(4): 2274-2279.
[32]
Abdou HW, Muqresh MA, Omer M. The potential role of CD44 and CD133 in colorectal stem cell cancer[J]. Cureus, 2022, 14(10): e30509.
[33]
Atashpour S, Fouladdel S, Movahhed TK, et al. Quercetin induces cell cycle arrest and apoptosis in CD133(+) cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin[J]. Iran J Basic Med Sci, 2015, 18(7): 635-643.
[34]
游雪娟,冯珂,纪立金, 等. 线粒体—中医"脾"与细胞凋亡相关理论研究[J]. 中医临床研究, 2025: 1-11.
[35]
董梁,张敬,缪柯. 川芎内酯抑制结肠癌细胞的生长和肿瘤干细胞样特性[J]. 广州中医药大学学报, 2021, 38(12): 2742-2750.
[36]
Nair JJ, van Staden J. Cell cycle modulatory effects of Amaryllidaceae alkaloids[J]. Life Sci, 2018, 213: 94-101.
[37]
杨君,刘军权,吕小婷, 等. 白藜芦醇抑制结肠癌干细胞增殖并增强mica/b的表达[J]. 细胞与分子免疫学杂志, 2015, 31(7): 889-893.
[38]
Vundavilli H, Datta A, Sima C, et al. Targeting oncogenic mutations in colorectal cancer using cryptotanshinone[J]. PLoS One, 2021, 16(2): e247190.
[39]
Fan X, Zhu M, Qiu F, et al. Curcumin may be a potential adjuvant treatment drug for colon cancer by targeting CD44[J]. Int Immunopharmacol, 2020, 88: 106991.
[40]
田传鑫,赵磊. 结直肠癌及结直肠癌肝转移流行病学特点[J]. 中华肿瘤防治杂志, 2021, 28(13): 1033-1038.
[41]
Kantara C, O’Connell MR, Luthra G, et al. Methods for detecting circulating cancer stem cells (CCSCs) as a novel approach for diagnosis of colon cancer relapse/metastasis[J]. Lab Invest, 2015, 95(1): 100-112.
[42]
张转红,刘婷,高飞云, 等. 中药抑制结肠癌血管生成的作用机制研究进展[J]. 中草药, 2023, 54(3): 948-955.
[43]
Tang YC, Zhang Y, Zhou J, et al. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo[J]. Int J Oncol, 2018, 52(1): 127-138.
[44]
谢光洪,赵逵. 姜黄素对人结肠癌肿瘤样干细胞中egf表达的作用[J]. 贵州医药, 2023, 47(7): 1017-1019.
[45]
Zhang N, Ng AS, Cai S, et al. Novel therapeutic strategies: targeting epithelial-mesenchymal transition in colorectal cancer[J]. Lancet Oncol, 2021, 22(8): e358-e368.
[46]
Lu J, Kornmann M, Traub B. Role of epithelial to mesenchymal transition in colorectal cancer[J]. Int J Mol Sci, 2023, 24(19): 14815.
[47]
Acikgoz E, Tatar C, Oktem G. Triptolide inhibits CD133(+) /CD44(+) colon cancer stem cell growth and migration through triggering apoptosis and represses epithelial-mesenchmal transition via downregulating expressions of snail, slug, and twist[J]. J Cell Biochem, 2020, 121(5-6): 3313-3324.
[48]
Hajjari M, Salavaty A. Hotair: an oncogenic long non-coding RNA in different cancers[J]. Cancer Biol Med, 2015, 12(1): 1-9.
[49]
郝钦,谭晓慧,王飞, 等. 莱菔子抑制结肠癌干细胞恶性行为的研究[J]. 中华中医药学刊, 2020, 38(10): 154-156.
[50]
蒋思沅,刘杰. 中药有效成分抗大肠癌转移实验研究进展[J]. 新中医, 2022, 54(23): 154-158.
[51]
王鑫,陈光伟,杨洋, 等. 扶正抗癌方合柴芍六君子汤联合贝伐珠单抗+folfox方案治疗转移性结直肠癌[J]. 现代中医药, 2020, 40(6): 70-76.
[52]
杨忠明,杨叶青,曾瑞, 等. 贞芪六君抑癌汤配合培美曲塞联合奈达铂方案化疗对Ⅲb~Ⅳa期肺腺癌的影响[J]. 成都医学院学报, 2018, 13(6): 677-680.
[53]
Safa AR. Drug and apoptosis resistance in cancer stem cells: a puzzle with many pieces[J]. Cancer Drug Resist, 2022, 5(4): 850-872.
[54]
Tao J, Sun RQ, Gu RX, et al. Astragali Radix-Curcumae Rhizoma inhibits colon cancer progression and enhances 5-FU efficacy by regulating hypoxia-inducible factors and tumor stem cells[J]. China Journal of Chinese Materia Medica, 2024, 49(4): 1044-1051.
[55]
Zhang Y, Wu Z, Yang Y, et al. Poziotinib inhibits the efflux activity of the ABCB1 and ABCG2 transporters and the expression of the ABCG2 transporter protein in multidrug resistant colon cancer cells[J]. Cancers (Basel), 2020, 12(11): 3249.
[56]
艾芳芳,肖红燕,汪芳, 等. 枸杞多糖联合奥沙利铂可逆转结肠癌干细胞的耐药[J]. 中国组织工程研究, 2024, 28(1): 74-79.
[57]
Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers[J]. Cell Death Dis, 2020, 11(9): 797.
[58]
Yu L, Wei J, Liu P. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer[J]. Semin Cancer Biol, 2022, 85: 69-94.
[59]
隋华,卫真真,王子元, 等. 左金丸调控PI3K/AKT/NF-κB信号通路对人大肠癌干细胞细胞耐药性的影响[J]. 上海中医药杂志, 2020, 54(S1): 127-131.
[60]
苏建伟,周喜汉,叶颖霞, 等. 苦参碱逆转人结肠癌干细胞化疗耐药作用及相关机制研究[J]. 现代免疫学, 2020, 40(6): 454-459.
[61]
Codrich M, Dalla E, Mio C, et al. Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN[J]. J Exp Clin Cancer Res, 2021, 40(1): 198.
[1] 杨春燕, 周晓苹. 机器人辅助技术在腹腔镜结直肠癌根治术中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(05): 584-588.
[2] 陈明付, 王庆惠, 纪辉涛, 陈银珍, 余小娟, 陈怀章, 赵虎, 王瑜. 基于CiteSpace 对结直肠癌铁死亡研究现状的可视化分析[J/OL]. 中华细胞与干细胞杂志(电子版), 2025, 15(03): 179-189.
[3] 陈伟, 周健, 包文霞, 崔建华. Circ-CCDC66通过与miR-618结合靶向PTEN调控结直肠癌进展[J/OL]. 中华细胞与干细胞杂志(电子版), 2025, 15(02): 82-92.
[4] 鲁旭, 李华. 结直肠癌肝转移肝移植治疗研究进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(04): 508-514.
[5] 中国医师协会结直肠肿瘤专业委员会免疫学组. 结直肠癌免疫治疗专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(04): 289-298.
[6] 中国医师协会结直肠肿瘤专业委员会术中放疗协作组. 结直肠癌术中放疗专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(04): 299-306.
[7] 中国医师协会结直肠肿瘤专业委员会. 结直肠癌卵巢转移诊疗专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(04): 307-318.
[8] 黄菊, 王猛, 韩冬. 双氢青蒿素通过JAK2/STAT3信号通路调节结直肠癌细胞的增殖、迁移、凋亡和免疫相关分子研究[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(04): 319-332.
[9] 姚金平, 郭涛, 张逸辰, 常磊, 冯雨舟, 崔精, 陈建欢, 鲍传庆. 基于免疫微环境分析探讨FN1与DOCK2在结肠癌中的预后价值[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(04): 333-344.
[10] 王飞, 张凯, 姚占胜. 一种信号通路水平结直肠癌细胞系选择新视角探讨[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(02): 179-183.
[11] 洪敏, 许建峰, 丰陈. 内脏型肥胖对结直肠癌根治术患者术后感染并发症的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(03): 199-204.
[12] 孟凡涛, 刘慧林, 杨爽. 老年结直肠癌组织RAB7A 表达与其临床病理特征及肝转移的关系[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(03): 205-209.
[13] 吴娟娟, 武海龙. 监测术前NLR、PLR 及SII 水平对全身麻醉下结直肠癌根治术后并发肠梗阻的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(03): 214-218.
[14] 王雅琪, 李杨亮, 路萍. 定量和定性粪便免疫化学检测在结直肠癌及进展期腺瘤筛查中的应用[J/OL]. 中华消化病与影像杂志(电子版), 2025, 15(03): 267-271.
[15] 张建秀, 聂娇, 杜超. 基于结肠镜标本的结肠癌类器官构建技术及临床科研应用前景探究[J/OL]. 中华胃肠内镜电子杂志, 2025, 12(02): 126-129.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?